Immunodermatology News

Bermekimab, which neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis, including a large reduction in pruritus, according to phase 2 trial results presented at the European Academy of Dermatology and Venereology Congress by Alice Gottlieb, MD, PhD, of Icahn School of Medicine at Mount Sinai.

Patients with moderate to severe alopecia areata who were assigned to CTP-543, an oral Janus kinase inhibitor from Concert Pharmaceuticals, achieved a 50% relative reduction in Severity of Alopecia Tool score at 24 weeks, according to data presented at the European Academy of Dermatology and Venereology Congress.

The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label reSURFACE1 trial, according to data presented at the European Academy of Dermatology and Venereology Congress.

SAN DIEGO — Early screening and early diagnosis are critical to managing systemic sclerosis, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

Patients receiving Enbrel for inflammatory diseases other than inflammatory bowel disease have an increased risk for a diagnosis of Crohn’s disease or ulcerative colitis, according to study results.

Significant differences in perceived risk factors for systemic disease along with other substantial differences exist in screening and treating children with discoid lupus erythematosus within and across dermatology and rheumatology, Lisa M. Arkin, MD, and colleagues found.

A group of international researchers writing in Pediatric Rheumatology have proposed a plan for tapering and discontinuing glucocorticoids in patients with juvenile-onset dermatomyositis, based on changes in core set measures of disease activity in the first 6 months of treatment.

Researchers were unable to identify the most effective antibiotic treatment for cellulitis, as no one antibiotic was superior over another based on available clinical trial data, according to researchers in JAMA Dermatology.

In adults with atopic dermatitis, treatment with cyclosporine or methotrexate appears to have a lower rate of serious infections than mycophenolate, azathioprine and systemic prednisone, according to a study.

In a paper recently published in Journal of the American Academy of Dermatology, researchers proposed there is a three-part pathogenesis of acute inflammatory edema, a form of pseudocellulitis commonly seen in critically ill patients.